Lowest Price Guaranteed From USD 4,899
Published
September 2020
Pages
330
View Count
4518
Example Insights
Report Description
The current market for non-invasive diagnostics for fibrotic diseases is expected to be worth $1.6 billion; it is likely to grow to $4.2 billion by 2030. With changing lifestyle and subsequently rising numbers of chronic ailments (such as obesity and diabetes), the prevalence of fibrotic diseases has also witnessed a surge globally. For instance, liver fibrosis is a common secondary pathological development observed in patients suffering from metabolic / cholestatic diseases, individuals consuming excessive quantities of alcohol and patients suffering from viral hepatitis. With non-alcoholic fatty liver disease (NAFLD) (subsequently progressing to nonalcoholic steatohepatitis / NASH) being the primary cause of liver disease, nearly 4.5 million adults in the US have been diagnosed with this condition in 2018. Similarly, idiopathic pulmonary fibrosis (IPF) is a chronic, progressive, life-threatening interstitial lung disease reported in individuals with high exposure to deadly pollutants, radiation treatments and chemotherapeutic drugs. Although, IPF is a rare disease, nearly 40,000 new cases are diagnosed in the Europe, annually. Early diagnosis of fibrotic diseases is crucial to the condition being successfully managed / treated. However, timely diagnosis of this medical condition has been a known challenge due to the absence of overt symptoms. When symptoms appear, the patient suspected with the disease is suggested to undergo tissue biopsy for the disease confirmation. Considering that a tissue biopsy, a painful and traumatic procedure, is the currently accepted standard of diagnosis, there is a stigma associated with the process. Moreover, owing to the invasive nature of the test, it cannot be frequently repeated in order to monitor disease progress or validate therapeutic outcomes. There is, therefore, an established unmet need for a safer and more patient friendly diagnostic method.
Advances in the field of biotechnology have enabled the development of several minimally invasive / non-invasive approaches for diagnosis of fibrotic diseases which include imaging diagnostics and biomarker-based assays. Among the biomarker-based tests, liquid biopsy (based on the analysis of biofluids such as blood, urine and / or plasma), a relatively new concept, has emerged as a versatile and promising non-invasive cancer diagnostic method for the detection of not only cancer but also fibrosis. In addition, there are numerous forms of genetic analysis which enable accurate diagnosis of diseases such as cystic fibrosis; these biomarker and genetic tests are backed by clinical data, validating their relevance and applicability across several types of fibrotic indications, and are anticipated to replace the existing invasive diagnostic techniques in the future.
The “Non-Invasive Diagnostics for Fibrotic Disease Market, 2020-2030” report features an extensive study of the current market landscape, offering an informed opinion on the likely adoption of these products over the next decade. It features an in-depth analysis, highlighting the capabilities of various stakeholders engaged in this domain. In addition to other elements, the study includes:
One of the key objectives of the report was to estimate the existing market size and the future opportunity for non-invasive diagnostics for fibrotic diseases, over the next decade. Based on multiple parameters, such as disease prevalence, anticipated adoption of non-invasive approaches for fibrotic diseases and their likely selling price, we have provided informed estimates on the evolution of the market for the period 2020-2030. The report also features the likely distribution of the current and forecasted opportunity across [A] target fibrotic disease (cystic fibrosis, liver fibrosis and pulmonary fibrosis) [B] end user (hospitals / clinics and research institutes) and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
The opinions and insights presented in the report were also influenced by discussions held with multiple stakeholders in this domain. The report features detailed transcripts of interviews held with the following individuals:
All actual figures have been sourced and analyzed from publicly available information forums. Financial figures mentioned in this report are in USD, unless otherwise specified.
Contents
Chapter 2 provides an executive summary of the insights captured in our research. It offers a high-level view on the state of the market for non-invasive diagnostics of fibrotic diseases, in the short-midterm and long term.
Chapter 3 provides a general overview of different types of fibrotic diseases and pathogenesis of the disease. In this section of the report, we have also highlighted the importance of early diagnosis and screening of the disease. The chapter outlines the conventional invasive diagnostic tests, which are widely used for diagnosis and prognosis, their limitations and the need / future opportunity of non-invasive approaches.
Chapter 4 presents information on different imaging techniques, screening assays and advanced approaches used for diagnosis of fibrosis, highlighting the advantages and disadvantages of each of the aforementioned techniques.
Chapter 5 includes information on more than 100 non-invasive products that are either developed or being developed for diagnosis of various fibrotic diseases. It features a detailed analysis of products, based on status of development (available or under development), type of products (assay-kits, devices and software), application area (diagnostics, monitoring, screening and research), target fibrotic disease (cardiac fibrosis, cystic fibrosis, liver fibrosis, pulmonary fibrosis and renal fibrosis), type of sample (blood, saliva, mucus and buccal swab), type of biomarker, end user (hospitals and clinics, research institutes and self-tests), turnaround time and requirement of medical assistance. In addition, the chapter provides information on product developer(s), and analysis based on year of their establishment, location of headquarters and employee strength.
Chapter 6 provides detailed profiles of some of the leading stakeholders in this field (shortlisted based on number of pipeline products). Each profile presents a brief overview of the company, its financial information (if available), product portfolio, recent developments and an informed future outlook.
Chapter 7 features an in-depth analysis and discussion on the various partnerships that have been inked among players in this market, during the time period between 2016 and 2020 (till May). It also includes a brief description of the various types of partnership models (distribution
acquisition, product development, joint venture, licensing, product utilization, clinical trial product development and commercialization and others) that have been adopted by stakeholders in this domain.
Chapter 8 provides a detailed analysis of more than 60 completed, ongoing and planned clinical studies for non-invasive diagnostics of fibrotic diseases, highlighting prevalent trends across various relevant parameters, such as current trial status, trial registration year, phase of development, study design, leading industry sponsors (in terms of number of trials conducted), study focus, product types, popular products, target fibrotic disease, enrolled patient population and regional distribution of trials.
Chapter 9 presents an insightful case study on biomarkers being evaluated for liver fibrosis, featuring analysis based on by type of biomarker and type of liver fibrosis, highlighting popular biomarkers and leading players (both industry and non-industry).
Chapter 10 includes an in-depth analysis of over 13,000 patents filed / granted for non-invasive diagnostic products for fibrotic diseases, highlighting key trends associated with these patents, across type of patent, publication year and application year, regional applicability, CPC symbols, emerging focus areas, leading patent assignees (in terms of number of patents filed / granted), patent benchmarking and valuation.
Chapter 11 features a detailed market forecast analysis, highlighting the likely growth of market for non-invasive diagnostics for fibrotic diseases, till the year 2030. We have segmented the opportunity based on [A] target fibrotic disease (cystic fibrosis, lung fibrosis and pulmonary fibrosis), [B] end user (hospitals / clinics and research institutes) and [C] key geographical regions (North America, Europe, Asia-Pacific, Latin America and Middle East and North Africa). In order to account for future uncertainties and to add robustness to our model, we have provided three market forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Chapter 12 summarizes the entire report. It presents a list of key takeaways and offers our independent opinion on the current market scenario. Further, it captures the evolutionary trends that are likely to determine the future of this segment of non-invasive diagnostics for fibrotic diseases.
Chapter 13 is a collection of interview transcripts of discussions held with key stakeholders in this market. The chapter provides a brief overview of the companies and details of interviews held with Gary de Jong (Chief Executive Officer, Repeat Diagnostics), Herman Steen (Chief Executive Officer, Biorion), Lawrence Cohen (Chief Executive Officer, Glycotest) and Charles Swindell (Chief Scientific Officer, Glycotest),
Chapter 14 is an appendix, which provides tabulated data and numbers for all the figures included in the report.
Chapter 15 is an appendix, which contains a list of companies and organizations mentioned in this report.
1. PREFACE
1.1. Scope of the Report
1.2. Research Methodology
1.3. Chapter Outlines
2. EXECUTIVE SUMMARY
3. INTRODUCTION
3.1. Chapter Overview
3.2. Overview of Fibrosis
3.3. Diagnostics of Fibrosis
3.4. Conventional Invasive Fibrosis Diagnostic Tests
3.4.1. Biopsy
3.4.2. Endoscopy
3.4.3. Radiology
3.4.4. Limitations of Conventional Diagnostics and Need for Non-Invasive Methods
3.5. Non-Invasive Diagnostic Techniques
3.5.1. Diagnostic Biomarkers
3.5.1.1 Biomarkers for Diagnosis of Liver Fibrosis
3.5.1.2 Biomarkers for Diagnosis of Kidney Fibrosis
3.5.1.3 Biomarkers for Diagnosis of Pulmonary Fibrosis
3.5.1.4 Biomarkers for Diagnosis of Cardiac Fibrosis
3.5.2. Imaging / Scanning Devices
3.6. Conclusion
4. CONCEPT OF NON-INVASIVE FIBROSIS SCREENING AND DIAGNOSTICS
4.1. Chapter Overview
4.2. Imaging / Scanning Based Diagnostics
4.2.1. Computerized Tomography (CT) Scan
4.2.2. Integrated Positron Emission Tomography (PET) -CT Scan
4.2.3. Magnetic Resonance Imaging (MRI)
4.2.4. Ultrasound
4.3. Screening Assays
4.3.1. Biomarker Tests
4.3.2. Digital Rectal Exam (DRE)
4.3.3. Fecal Occult Blood Tests (FOBT)
4.4. Advanced Non-invasive Approaches
4.4.1. Cytogenetic / Gene Expression Studies
4.4.2. Liquid Biopsy
4.4.3. Optical Biopsy
4.4.4. Saliva-Based Oral Fibrosis Diagnostics
4.4.5. Vital Staining
5. MARKET LANDSCAPE
5.1. Chapter Overview
5.2. Non-Invasive Diagnostics for Fibrotic Diseases: Overall Market Landscape
5.2.1. Analysis by Status of Development
5.2.2. Analysis by Type of Product
5.2.3. Analysis by Application Area
5.2.4. Analysis by Target Fibrotic Disease
5.2.5. Analysis by Type of Product and Target Fibrotic Disease
5.2.6. Analysis by Type of Sample
5.2.7. Analysis by Type of Biomarker
5.2.8. Analysis by End User
5.2.9. Heat Map Analysis by Target Fibrotic Disease and End User
5.2.10. Analysis by Turnaround Time
5.2.11. Analysis by Requirement of Medical Assistance
5.4. Non-Invasive Diagnostics for Fibrotic Diseases: List of Developers
5.4.1. Analysis by Year of Establishment
5.4.2. Analysis by Company Size
5.4.3. Analysis by Geographical Location
5.4.4. Leading Developers: Analysis by Number of Products
6. COMPANY PROFILES
6.1. Chapter Overview
6.2. BioPredictive
6.2.1. Company Overview
6.2.2. Financial Information
6.2.3. Non-Invasive Diagnostics Portfolio
6.2.4. Recent Developments and Future Outlook
6.3. Echosens
6.3.1. Company Overview
6.3.2. Financial Information
6.3.3. Non-Invasive Diagnostics Portfolio
6.3.4. Recent Developments and Future Outlook
6.4. ELITechGroup
6.4.1. Company Overview
6.4.2. Financial Information
6.4.3. Non-Invasive Diagnostics Portfolio
6.4.4. Recent Developments and Future Outlook
6.5. Fibronostics
6.5.1. Company Overview
6.5.2. Financial Information
6.5.3. Non-Invasive Diagnostics Portfolio
6.5.4. Recent Developments and Future Outlook
6.6. Fujirebio
6.6.1. Company Overview
6.6.2. Financial Information
6.6.3. Non-Invasive Diagnostics Portfolio
6.6.4. Recent Developments and Future Outlook
6.7. GenPath Diagnostics
6.7.1. Company Overview
6.7.2. Financial Information
6.7.3. Non-Invasive Diagnostics Portfolio
6.7.4. Recent Developments and Future Outlook
6.8. HepQuant
6.8.1. Company Overview
6.8.2. Financial Information
6.8.3. Non-Invasive Diagnostics Portfolio
6.8.4. Recent Developments and Future Outlook
6.9. LabCorp
6.9.1. Company Overview
6.9.2. Financial Information
6.9.3. Non-Invasive Diagnostics Portfolio
6.9.4. Recent Developments and Future Outlook
6.10. Luminex
6.10.1. Company Overview
6.10.2. Financial Information
6.10.3. Non-Invasive Diagnostics Portfolio
6.10.4. Recent Developments and Future Outlook
6.11. Oasis Diagnostics
6.11.1. Company Overview
6.11.2. Financial Information
6.11.3. Non-Invasive Diagnostics Portfolio
6.11.4. Recent Developments and Future Outlook
6.12. PerkinElmer
6.12.1. Company Overview
6.12.2. Financial Information
6.12.3. Non-Invasive Diagnostics Portfolio
6.12.4. Recent Developments and Future Outlook
6.13. Yourgene Health
6.13.1. Company Overview
6.13.2. Financial Information
6.13.3. Non-Invasive Diagnostics Portfolio
6.13.4. Recent Developments and Future Outlook
7. PARNERSHIPS AND COLLABORATIONS
7.1. Chapter Overview
7.2. Partnership Models
7.3. Non-Invasive Diagnostics for Fibrotic Diseases: List of Partnerships and Collaborations
7.3.1. Analysis by Year of Partnership
7.3.2. Analysis by Type of Partnership
7.3.3. Analysis by Type of Product
7.3.4. Most Popular Products: Analysis by Number of Partnerships
7.3.5. Analysis by Target Fibrotic Disease
7.3.6. Analysis by Year of Partnership and Type of Partner
7.3.7. Analysis by Type of Partnership and Type of Partner
7.3.8. Most Active Players: Analysis by Number of Partnerships
7.4. Regional Analysis
7.4.1. Intercontinental and Intracontinental Agreements
8. CLINICAL TRIAL ANALYSIS
8.1. Chapter Overview
8.2. Scope and Methodology
8.3. Non-Invasive Diagnostics for Fibrotic Diseases: Clinical Trial Analysis
8.3.1. Analysis by Trial Registration Year
8.3.2. Analysis by Trial Recruitment Status
8.3.3. Analysis by Trial Registration Year and Number of Patients Enrolled
8.3.4. Analysis by Study Design
8.3.5. Analysis by Type of Sponsor / Collaborator
8.3.6. Leading Players: Analysis by Number of Registered Trials
8.3.7. Word Cloud: Key Focus Areas
8.3.8. Analysis by Target Fibrotic Disease
8.3.9. Popular Product Types: Analysis by Number of Registered Trials
8.3.10. Popular Products: Analysis by Number of Registered Trials
8.3.11. Heat Map Analysis by Target Fibrotic Disease and Product Type
8.3.12. Geographical Analysis by Number of Registered Trials
8.3.13. Geographical Analysis by Number of Patients Enrolled
9. CASE STUDY: BIOMARKER ANALYSIS FOR LIVER FIBROSIS
9.1. Chapter Overview
9.2. Scope and Methodology
9.3. Non-Invasive Diagnostics for Fibrotic Diseases: Biomarker Analysis for Liver Fibrosis
9.3.1. Analysis by Type of Biomarker
9.3.2. Analysis by Trial Phase and Type of Biomarker
9.3.3. Analysis by Type of Liver Fibrosis
9.3.4. Popular Biomarkers: Analysis by Number of Registered Trials
9.3.5. Heat Map Analysis by Popular Biomarkers and Trial Phase
9.3.6. Word Cloud Analysis: Popular and Emerging Biomarkers
9.3.7. Leading Players: Analysis by Number of Registered Trials
9.3.8. Heat Map Analysis by Popular Biomarkers and Leading Industry Players
9.3.9. Heat Map Analysis by Popular Biomarkers and Leading Non-industry Players
10. PATENT ANALYSIS
10.1. Chapter Overview
10.2. Scope and Methodology
10.3. Non-Invasive Diagnostics for Fibrotic Diseases: Patent Analysis
10.3.1. Analysis by Type of Patent
10.3.2. Analysis by Publication Year
10.3.3. Analysis by Issuing Authority / Patent Offices Involved
10.3.4. Analysis by CPC Symbols
10.3.5. Emerging Focus Areas
10.3.6. Leading Players: Analysis by Number of Patents
10.4. Non-Invasive Diagnostics for Fibrotic Diseases: Patent Benchmarking Analysis
10.4.1. Analysis by Patent Characteristics
10.5. Non-Invasive Diagnostics for Fibrotic Diseases: Patent Valuation Analysis
10.6. Leading Patents by Number of Citations
11. MARKET SIZING AND OPPORTUNITY ANALYSIS
11.1. Chapter Overview
11.2. Forecast Methodology and Key Assumptions
11.3. Global Non-Invasive Diagnostics for Fibrotic Diseases Market, 2020-2030
11.4. Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Target Fibrotic Disease
11.4.1. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Cystic Fibrosis, 2020-2030
11.4.2. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Liver Fibrosis, 2020-2030
11.4.3. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Pulmonary Fibrosis, 2020-2030
11.5. Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by End User, 2020-2030
11.5.1. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Hospitals, 2020-2030
11.5.2. Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Research Institutes, 2020-2030
11.6. Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Region
11.6.1. Non-Invasive Diagnostics for Fibrotic Diseases Market in North America, 2020-2030
11.6.2. Non-Invasive Diagnostics for Fibrotic Diseases Market in Europe, 2020-2030
11.6.3. Non-Invasive Diagnostics for Fibrotic Diseases Market in Asia Pacific, 2020-2030
11.6.4. Non-Invasive Diagnostics for Fibrotic Diseases Market in Latin America, 2020-2030
11.6.5. Non-Invasive Diagnostics for Fibrotic Diseases Market in Middle East and North Africa, 2020-2030
12. CONCLUDING REMARKS
12.1. Chapter Overview
12.2. Key Takeaways
13. EXECUTIVE INSIGHTS
13.1. Chapter Overview
13.2. Biorion
13.2.1. Company Snapshot
13.2.2. Interview Transcript: Herman Steen, Chief Executive Officer, Biorion
13.3. Glycotest
13.3.1. Company Snapshot
13.3.2. Interview Transcript: Lawrence Cohen, Chief Executive Officer and Charles Swindell, Chief Scientific Officer
13.4. Repeat Diagnostics
13.4.1. Company Snapshot
13.4.2. Interview Transcript: Garry de Jong, Chief Executive Officer, Repeat Diagnostics
14. APPENDIX 1: TABULATED DATA
15. APPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS
Figure 3.1 Molecular Mechanism Involved in Fibrosis
Figure 3.2 Pathological Characteristics of Fibrosis in Different Organs
Figure 4.1 Non-Invasive Screening and Diagnosis of Fibrosis
Figure 4.2 Types of Diagnostic Imaging
Figure 4.3 Types of Screening Assays
Figure 4.4 Types of Advanced Non-Invasive Approaches
Figure 5.1 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Status of Development
Figure 5.2 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Product
Figure 5.3 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Application Area
Figure 5.4 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Target Fibrotic Disease
Figure 5.5 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Product and Target Fibrotic Disease
Figure 5.6 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Sample
Figure 5.7 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Biomarker
Figure 5.7 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by
Figure 5.8 Heat Map Analysis: Distribution by Target Fibrotic Disease and End User
Figure 5.9 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Turnaround Time
Figure 5.10 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Requirement of Medical Assistance
Figure 5.11 Product Developers: Distribution by Year of Establishment
Figure 5.12 Product Developers: Distribution by Company Size
Figure 5.13 Product Developers: Distribution by Geographical Location
Figure 5.14 Leading Developers: Distribution by Number of Products
Figure 6.1 BioPredictive: Annual Revenues, 2016-2020 (USD Billion)
Figure 6.2 Echosens: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.3 ELITechGroup: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.4 Fibronotics: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.5 Fujirebio: Annual Revenues, 2016-2020 (USD Billion)
Figure 6.6 GenPath Diagnostics: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.7 HepQuant: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.8 LabCorp: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.9 Luminex: Annual Revenues, 2016-2020 (USD Billion)
Figure 6.10 Oasis Diagnostics: Annual Revenues, 2016-2019 (USD Billion)
Figure 6.11 PerkinElmer: Annual Revenues, 2016-2020 (USD Billion)
Figure 6.12 Yourgene Health: Annual Revenues, 2016-2019 (USD Billion)
Figure 7.1 Partnerships and Collaborations: Distribution by Year of Partnership
Figure 7.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 7.3 Partnerships and Collaborations: Distribution by Type of Product
Figure 7.4 Most Popular Products: Distribution by Number of Partnerships
Figure 7.5 Partnerships and Collaborations: Distribution by Target Fibrotic Disease
Figure 7.6 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Figure 7.7 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Figure 7.8 Most Active Players: Distribution by Number of Partnerships
Figure 7.9 Partnerships and Collaborations: Regional Analysis
Figure 7.10 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Figure 8.1 Clinical Trial Analysis: Distribution by Trial Status
Figure 8.2 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020 (till June)
Figure 8.3 Clinical Trial Analysis: Cumulative Year-wise Trend in Number of Patients Enrolled, Pre-2010-2020 (till June)
Figure 8.4 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Figure 8.5 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2002-2020 (till June)
Figure 8.6 Clinical Trial Analysis: Distribution by Study Design
Figure 8.7 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 8.8 Leading Players: Analysis by Number of Trials
Figure 8.9 Word Cloud Analysis: Distribution by Focus Area
Figure 8.10 Clinical Trial Analysis: Distribution by Target Fibrotic Disease
Figure 8.11 Popular Product(s): Distribution by Number of Registered Trials
Figure 8.12 Popular Product Types: Distribution by Number of Registered Trials
Figure 8.13 Popular Product Types: Distribution by Status of Clinical Trials
Figure 8.14 Heat Map Analysis: Analysis by Target Fibrotic Disease and Type of Product
Figure 8.15 Clinical Trial Analysis: Geographical Distribution by Number of Registered Trials
Figure 8.16 Clinical Trial Analysis: Geographical Distribution by Number of Patients Enrolled
Figure 9.1 Biomarker Analysis for Liver Fibrosis: Scope and Methodology
Figure 9.2 Biomarker Analysis for Liver Fibrosis: Distribution by Type of Biomarker
Figure 9.3 Biomarker Analysis for Liver Fibrosis: Distribution by Trial Phase and Type of Biomarker
Figure 9.4 Biomarker Analysis for Liver Fibrosis: Distribution by Type of Liver Fibrosis
Figure 9.5 Popular Biomarkers: Distribution by Number of Registered Trials
Figure 9.6 Heat Map Analysis: Analysis by Popular Biomarkers and Trial Phase
Figure 9.7 Word Cloud Analysis: Popular and Emerging Biomarkers
Figure 9.8 Leading Players: Distribution by Number of Registered Trials
Figure 9.9 Heat Map Analysis: Distribution by Popular Biomarkers and Leading Industry Players
Figure 9.10 Heat Map Analysis: Distribution by Popular Biomarkers and Leading Non-industry Players
Figure 10.1 Patent Analysis: Distribution by Type of Patent
Figure 10.2 Patent Analysis: Distribution by Publication Year
Figure 10.3 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involved
Figure 10.4 Patent Analysis: Distribution by CPC Symbols
Figure 10.5 Patent Analysis: Emerging Focus Areas
Figure 10.6 Patent Analysis: Cumulative Distribution by Type of Organization
Figure 10.7 Patent Analysis: Leading Industry Players
Figure 10.8 Patent Analysis: Leading Non-Industry Players
Figure 10.9 Patent Analysis: Leading Individual Assignees
Figure 10.10 Patent Analysis (Industry Players): Benchmarking by Patent Characteristics
Figure 10.11 Patent Analysis: Distribution of Patents by Age
Figure 10.12 Non-Invasive Diagnostics for Fibrotic Diseases: Patent Valuation
Figure 11.1 Global Non-Invasive Diagnostics for Fibrotic Diseases Market, 2020-2030 (USD Million)
Figure 11.2 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Target Fibrotic Disease, 2025 and 2030
Figure 11.3 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Cystic Fibrosis, 2020-2030 (USD Million)
Figure 11.4 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Liver Fibrosis, 2020-2030 (USD Million)
Figure 11.5 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Pulmonary Fibrosis, 2020-2030 (USD Million)
Figure 11.6 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by End Users, 2025 and 2030
Figure 11.7 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Hospitals and Clinics 2020-2030 (USD Million)
Figure 11.8 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Research Institutes 2020-2030 (USD Million)
Figure 11.9 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Region, 2025 and 2030
Figure 11.10 Non-Invasive Diagnostics for Fibrotic Diseases Market in North America, 2020- 2030 (USD Million)
Figure 11.11 Non-Invasive Diagnostics for Fibrotic Diseases Market in Europe, 2020-2030 (USD Million)
Figure 11.12 Non-Invasive Diagnostics for Fibrotic Diseases Market in Asia Pacific, 2020-2030 (USD Million)
Figure 11.13 Non-Invasive Diagnostics for Fibrotic Diseases Market in Latin America, 2020-2030 (USD Million)
Figure 11.14 Non-Invasive Diagnostics for Fibrotic Diseases Market in Middle East and North Africa, 2020-2030 (USD Million)
Table 3.1 Cost of Biopsy of Different Organs (in USD)
Table 4.1 List of Biomarkers for Fibrotic Diseases
Table 5.1 List of Non-Invasive Diagnostics for Fibrotic Diseases
Table 5.2 Non-Invasive Diagnostics for Fibrotic Diseases: List of Product Developers
Table 6.1 Non-Invasive Diagnostics for Fibrotic Diseases: List of Companies Profiled
Table 6.2 Product Profile: FibroTest®
Table 6.3 Product Profile: ActiTest®
Table 6.4 Product Profile: NashTest®
Table 6.5 BioPredictive: Recent Developments and Future Outlook
Table 6.6 Product Profile: FIBROSCAN® 530 COMPACT
Table 6.7 Product Profile: FIBROSCAN® 430 MINI
Table 6.8 Product Profile: FIBROSCAN® 502 TOUCH
Table 6.9 Product Profile: FibroMeter™
Table 6.10 Echosens: Recent Developments and Future Outlook
Table 6.11 Product Profile: Macroduct® Sweat Collection System
Table 6.12 Product Profile: Sweat-Chek™ Analyzer
Table 6.13 Product Profile: Nanoduct® Neonatal Sweat Analysis System
Table 6.14 Product Profile: ChloroChek® Chloridometer®
Table 6.15 ELITechGroup: Recent Developments and Future Outlook
Table 6.16 Product Profile: TAEUS™
Table 6.17 Product Profile: LIVERFASt™
Table 6.18 Product Profile: LIVERFACt
Table 6.19 Product Profile: SteatoTEST
Table 6.20 Product Profile: LIVERFASt Select
Table 6.21 Product Profile: HealthFACTR
Table 6.22 Fibronotics: Recent Developments and Future Outlook
Table 6.23 Product Profile: INNO-LIPA® CFTR Deletions+6
Table 6.24 Product Profile: INNO-LiPA® CFTR iage
Table 6.25 Product Profile: INNO-LiPA® CFTR 17+Tn Update
Table 6.26 Product Profile: INNO-LiPA® CFTR 19
Table 6.27 Product Profile: INNO-LiPA® CFTR Italian Regional
Table 6.28 Product Profile: INNO-LiPA® CFTR Extra
Table 6.29 Product Profile: LiRAS® for LiPA® Cystic Fibrosis
Table 6.30 Product Profile: CFTR Sequencing and Deletion/Duplication Analysis
Table 6.31 Fujirebio: Recent Developments and Future Outlook
Table 6.32 Product Profile: CF Basic Carrier Screen
Table 6.33 Product Profile: Expanded CF Carrier Screen
Table 6.34 Product Profile: Cystic Fibrosis Poly T Analysis
Table 6.35 GenPath Diagnostics: Recent Developments and Future Outlook
Table 6.36 Product Profile: HepQuant® SHUNT
Table 6.37 Product Profile: HepQuant® FLOW
Table 6.38 Product Profile: HepQuant® STAT
Table 6.39 HepQuant: Recent Developments and Future Outlook
Table 6.40 Product Profile: NASH FibroSure®
Table 6.41 Product Profile: ASH FibroSure®
Table 6.42 Product Profile: Hepatitis C Virus (HCV) FibroSure®
Table 6.43 LabCorp: Recent Developments and Future Outlook
Table 6.44 Product Profile: xTAG® CF39v2 Kit
Table 6.45 Product Profile: xTAG® CF60v2 Kit
Table 6.46 Product Profile: xTAG® CF71v2 Kit
Table 6.47 Product Profile: Verigene CFTR and Verigene CFTR PolyT Nucleic Acid Tests
Table 6.48 Product Profile: MultiCode-PLx System
Table 6.49 Product Profile: INTROL® CF Panel III Control
Table 6.50 Luminex: Recent Developments and Future Outlook
Table 6.51 Product Profile: CF StripAssay® GER
Table 6.52 Product Profile: CF StripAssay® TUR
Table 6.53 Product Profile: CF StripAssay®
Table 6.54 Oasis Diagnostics: Recent Developments and Future Outlook
Table 6.55 Product Profile: GSP® Neonatal IRT kit
Table 6.56 Product Profile: AutoDELFIA® Neonatal IRT kit
Table 6.57 Product Profile: DELFIA® Neonatal IRT kit
Table 6.58 Product Profile: StepOne Newborn Screening Panel
Table 6.59 PerkinElmer: Recent Developments and Future Outlook
Table 6.60 Product Profile: EU2v1
Table 6.61 Product Profile: CF4v2
Table 6.62 Product Profile: CF30v2
Table 6.63 Yourgene Health: Recent Developments and Future Outlook
Table 7.1 Non-Invasive Diagnostics for Fibrotic Diseases: List of Partnerships and Collaborations
Table 12.1 Non-Invasive Diagnostics for Fibrotic Diseases: Summary of the Competitive Insights
Table 13.1 Biorion: Key Highlights
Table 13.2 Glycotest: Key Highlights
Table 13.3 Repeat Diagnostics: Key Highlights
Table 14.1 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Status of Development
Table 14.2 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Product
Table 14.3 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Application Area
Table 14.4 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Target Fibrotic Disease
Table 14.5 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Product and Target Fibrotic Disease
Table 14.6 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Sample
Table 14.7 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Type of Biomarker
Table 14.8 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Turnaround Time
Table 14.9 Non-Invasive Diagnostics for Fibrotic Diseases: Distribution by Requirement of Medical Assistance
Table 14.10 Product Developers: Distribution by Year of Establishment
Table 14.11 Product Developers: Distribution by Company Size
Table 14.12 Product Developers: Distribution by Geographical Location
Table 14.13 Leading Players: Distribution by Number of Products
Table 14.14 BioPredictive: Annual Revenues, 2016-2019 (USD Billion)
Table 14.15 Echosens: Annual Revenues, 2016-2019 (USD Billion)
Table 14.16 ELITechGroup: Annual Revenues, 2016-2019 (USD Billion)
Table 14.17 Fibronotics: Annual Revenues, 2016-2019 (USD Billion)
Table 14.18 Fujirebio: Annual Revenues, 2016-2019 (USD Billion)
Table 14.19 GenPath Diagnostics: Annual Revenues, 2016-2019 (USD Billion)
Table 14.20 HepQuant: Annual Revenues, 2016-2019 (USD Billion)
Table 14.21 LabCorp: Annual Revenues, 2016-2019 (USD Billion)
Table 14.22 Luminex: Annual Revenues, 2016-2020 (USD Billion)
Table 14.23 Oasis Diagnostics: Annual Revenues, 2016-2019 (USD Billion)
Table 14.24 PerkinElmer: Annual Revenues, 2016-2019 (USD Billion)
Table 14.25 Yourgene Health: Annual Revenues, 2016-2019 (USD Billion)
Table 14.26 Partnerships and Collaborations: Distribution by Year of Partnership
Table 14.27 Partnerships and Collaborations: Distribution by Type of Partnership
Table 14.28 Partnerships and Collaborations: Distribution by Type of Product
Table 14.29 Most Popular Products: Distribution by Number of Partnerships
Table 14.30 Partnerships and Collaborations: Distribution by Target Fibrotic Disease
Table 14.31 Partnerships and Collaborations: Distribution by Year of Partnership and Type of Partner
Table 14.32 Partnerships and Collaborations: Distribution by Type of Partnership and Type of Partner
Table 14.33 Most Active Players: Distribution by Number of Partnerships
Table 14.34 Partnerships and Collaborations: Regional Analysis
Table 14.35 Partnerships and Collaborations: Intercontinental and Intracontinental Agreements
Table 14.36 Clinical Trial Analysis: Distribution by Trial Status
Table 14.37 Clinical Trial Analysis: Cumulative Distribution of Trials by Registration Year, Pre-2010-2020 (till June)
Table 14.38 Clinical Trial Analysis: Cumulative Year-wise Trend in Number of Patients Enrolled, Pre-2010-2020 (till June)
Table 14.39 Clinical Trial Analysis: Distribution by Trial Recruitment Status
Table 14.40 Clinical Trial Analysis: Distribution by Number of Patients Enrolled by Trial Registration Year, Pre-2002-2020 (till June)
Table 14.41 Clinical Trial Analysis: Distribution by Study Design
Table 14.42 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 14.43 Leading Players: Analysis by Number of Trials
Table 14.44 Popular Product(s): Distribution by Number of Registered Trials
Table 14.45 Biomarker Analysis for Liver Fibrosis: Distribution by Type of Biomarker
Table 14.46 Biomarker Analysis for Liver Fibrosis: Distribution by Trial Phase and Type of Biomarker
Table 14.47 Biomarker Analysis for Liver Fibrosis: Distribution by Type of Liver Fibros
Table 14.48 Popular Biomarkers: Distribution by Number of Registered Trials
Table 14.49 Leading Players: Distribution by Number of Registered Trials
Table 14.50 Patent Analysis: Distribution by Type of Patent
Table 14.51 Patent Analysis: Distribution by Publication Year
Table 14.52 Patent Analysis: Distribution by Issuing Authority / Patent Offices Involve
Table 14.53 Patent Analysis: Distribution by CPC Symbols
Table 14.54 Patent Analysis: Cumulative Distribution by Type of Organization
Table 14.55 Patent Analysis: Leading Industry Players
Table 14.56 Patent Analysis: Leading Non-Industry Players
Table 14.57 Patent Analysis: Leading Individual Assignees
Table 14.58 Patent Analysis (Industry Players): Benchmarking by Patent Characteristics
Table 14.59 Patent Analysis: Distribution of Patents by Age
Table 14.60 Non-Invasive Diagnostics for Fibrotic Diseases: Patent Valuation
Table 14.61 Global Non-Invasive Diagnostics for Fibrotic Diseases Market, 2020-2030 (USD Million)
Table 14.62 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Indication, 2025 and 2030
Table 14.63 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Cystic Fibrosis, 2020-2030 (USD Million)
Table 14.64 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Liver Fibrosis, 2020-2030 (USD Million)
Table 14.65 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Pulmonary Fibrosis, 2020-2030 (USD Million)
Table 14.66 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by End Users, 2025 and 2030
Table 14.67 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Hospitals and Clinics 2020-2030 (USD Million)
Table 14.68 Global Non-Invasive Diagnostics for Fibrotic Diseases Market for Research Institutes 2020-2030 (USD Million)
Table 14.69 Global Non-Invasive Diagnostics for Fibrotic Diseases Market: Distribution by Region, 2025 and 2030
Table 14.70 Non-Invasive Diagnostics for Fibrotic Diseases Market in North America, 2020-2030 (USD Million)
Table 14.71 Non-Invasive Diagnostics for Fibrotic Diseases Market in Europe, 2020-2030 (USD Million)
Table 14.72 Non-Invasive Diagnostics for Fibrotic Diseases Market in Asia Pacific, 2020-2030 (USD Million)
Table 14.73 Non-Invasive Diagnostics for Fibrotic Diseases Market in Middle East and North Africa, 2020-2030 (USD Million)